Cyto Dyn Inc. CYDY
We take great care to ensure that the data presented and summarized in this overview for CytoDyn Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYDY
View all-
Eagle Bay Advisors LLC New York, NY162KShares$19,4530.01% of portfolio
-
Mai Capital Management47.5KShares$5,6970.0% of portfolio
-
Diversified Trust CO45.8KShares$5,4940.0% of portfolio
-
Williams Jones Wealth Management, Llc. New York, NY45KShares$5,4000.0% of portfolio
-
Rfp Financial Group LLC Atlanta, GA41.5KShares$4,9740.0% of portfolio
-
Next Capital Management LLC32.5KShares$3,9000.0% of portfolio
-
Horizon Financial Services, LLC18.2KShares$2,1840.0% of portfolio
-
Ancora Advisors, LLC Cleveland, OH9.49KShares$1,1380.0% of portfolio
-
Caz Investments LP Houston, TX4KShares$4800.0% of portfolio
Latest Institutional Activity in CYDY
Top Purchases
Top Sells
About CYDY
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (?COVID-19?). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Insider Transactions at CYDY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2023
|
Arvin Cyrus Arman President |
BUY
Grant, award, or other acquisition
|
Direct |
434,782
+28.68%
|
-
|
|
Nov 30
2022
|
Scott A. Kelly CMO |
BUY
Grant, award, or other acquisition
|
Direct |
16,927
+0.77%
|
-
|
|
Nov 30
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,008
+6.15%
|
-
|
|
Nov 15
2022
|
Nitya G. Ray Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,671
+2.66%
|
-
|
|
Nov 15
2022
|
Scott A. Kelly CMO |
BUY
Grant, award, or other acquisition
|
Direct |
15,234
+0.7%
|
-
|
|
Nov 15
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,807
+5.94%
|
-
|
|
Oct 31
2022
|
Nitya G. Ray Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,084
+3.2%
|
-
|
|
Oct 31
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,714
+7.34%
|
-
|
|
Oct 31
2022
|
Scott A. Kelly CMO |
BUY
Grant, award, or other acquisition
|
Direct |
17,922
+0.83%
|
-
|
|
Oct 15
2022
|
Nitya G. Ray Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,428
+2.57%
|
-
|
|
Oct 15
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
9,824
+6.24%
|
-
|
|
Oct 15
2022
|
Scott A. Kelly CMO |
BUY
Grant, award, or other acquisition
|
Direct |
13,849
+0.64%
|
-
|
|
Sep 30
2022
|
Nitya G. Ray Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,020
+2.76%
|
-
|
|
Sep 30
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,292
+6.95%
|
-
|
|
Sep 30
2022
|
Scott A. Kelly CMO |
BUY
Grant, award, or other acquisition
|
Direct |
18,793
+0.88%
|
-
|
|
Sep 20
2022
|
Arvin Cyrus Arman President |
BUY
Grant, award, or other acquisition
|
Direct |
646,552
+50.0%
|
-
|
|
Sep 15
2022
|
Scott A. Kelly CMO |
BUY
Grant, award, or other acquisition
|
Direct |
9,457
+0.45%
|
-
|
|
Sep 15
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,086
+5.26%
|
-
|
|
Sep 15
2022
|
Nitya G. Ray Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,965
+1.98%
|
-
|
|
Aug 31
2022
|
Antonio Migliarese CFO |
BUY
Grant, award, or other acquisition
|
Direct |
8,313
+6.45%
|
-
|